Return to: Pediatrics : Medical School : Academic Health Center : myU : U of M Home

Gold University of Minnesota M. Skip to main content. Link to University of Minnesota homepage
Division of Infectious Diseases, Department of Pediatrics
Whats Inside
For Patients and Families

Research

Education

Faculty

Contact Us

 

Peds ID Home


University Pediatrics Foundation - Make a Gift

Viking Children's Fund

Children's Cancer Research Fund

Department of Pediatrics > Home > Faculty > Mark R. Schleiss, M.D.

Printer-friendly version   Mail this page to a friend

Mark R. Schleiss, M.D.


Dr. Mark Schleiss Professor, Pediatrics
Director, Division of Pediatric Infectious Diseases
American Legion Chair of Pediatrics
Associate Chair for Research, Department of Pediatrics
MMC 296
420 Delaware Street, SE
Minneapolis, MN  55455
Phone: (612) 624-1966
Fax: (612) 624-8927
schleiss@umn.edu

Mark R. Schleiss, M.D. is a Professor of Pediatrics in the division of Infectious Diseases. Dr. Schleiss is the Director, Division of  Infectious Diseases, Associate Head for Reseach, Department of Pediatrics and the American Legion Chair of Pediatrics.

Dr. Schleiss received his M.D. degree from the Oregon Health and Sciences University, Portland, Oregon. He completed his residency at Doernbecher Children’s Hospital, Oregon Health and Sciences University, Portland, Oregon and his Pediatric Infectious Diseases fellowship at Children’s Hospital Medical Center, University of Washington, Seattle, Washington and a fellowship in Molecular Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington

Honors

1979 Associate Member, Sigma Xi Research Honor Society, Stanford, California
1995 Distinguished Service Award, Association for Retarded Citizens (ARC)
1999 Mead-Johnson Teaching Award
2000-2003 Society for Pediatric Research, Council Member (www.aps-spr.org)
2001-present Council Member, Federation of Pediatric Organizations (FOPO) and Pediatric Education Steering Committee (PESC), www.fopo.org
2003, 2004 Golden Spoon House Staff Teaching Award
2005-present Society for Pediatric Research, Secretary - Treasurer ( www.aps-spr.org )

Selected Recent Publications

Schleiss MR, Jensen NJ. Cloning and expression of the guinea pig cytomegalovirus glycoprotein B (gB) in a recombinant baculovirus: utility for vaccine studies for the prevention of experimental infection. J Virol Methods. 2003;108(1):59-65.

Schleiss MR, Bourne N, Bravo FJ, et al. Quantitative-competitive PCR monitoring of viral load following experimental guinea pig cytomegalovirus infection. J Virol Methods. 2003;108(1):103-10.

Schleiss MR. Vertically transmitted herpesvirus infections. Herpes. 2003;10(1):4-11.

Xanthakos SA, Schleiss MR. Glycoprotein B genotyping of cytomegalovirus strains isolated in a pediatric population. Pediatr Infect Dis J. 2003;22(5):462-3.

Haggerty SM, Schleiss MR. A novel CC-chemokine homolog encoded by guinea pig cytomegalovirus. Virus Genes. 2002;25(3):271-9.

Penfold M, Miao Z, Wang Y, Haggerty S, Schleiss MR. A macrophage inflammatory protein homolog encoded by guinea pig cytomegalovirus signals via CC chemokine receptor 1. Virology. 2003;316(2):202-12.

Schleiss MR, Bourne N, Bernstein DI. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis. 2003;188(12):1868-74.

McGregor A, Schleiss MR. Herpesvirus genome mutagenesis by transposon-mediated strategies. Methods Mol Biol. 2004;256:281-302.

McGregor A, Liu F, Schleiss MR. Identification of essential and non-essential genes of the guinea pig cytomegalovirus (GPCMV) genome via transposome mutagenesis of an infectious BAC clone. Virus Res. 2004;101(2):101-8.

Schleiss MR, Bourne N, Stroup G, et al. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis. 2004;189(8):1374-81.

McGregor A, Liu F, Schleiss MR. Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83). J Virol. 2004;78(18):9872-89.

Blackman SC , Lurain NS , Witte DP, Filipovich AH, Groen P, Schleiss MR. Emergence and compartmentalization of fatal multi-drug-resistant cytomegalovirus infection in a patient with autosomal-recessive severe combined immune deficiency. J Pediatr Hematol Oncol. 2004;26(9):601-5.

Schleiss MR, McVoy MA. Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy. Expert Rev Anti Infect Ther. 2004;2(3):389-403.

Schleiss MR, Bernstein DI, Passo M, Parker S, Meric C, Verdier F, Newkirk MM. Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects. Vaccine. 2004;23(5):687-92.

Schleiss MR, Bernstein DI, McVoy MA, Stroup G, Bravo F, Creasy B, McGregor A, Henninger K, Hallenberger S. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res. 2005;65(1):35-43.

Schleiss MR. Antiviral therapy of congenital cytomegalovirus infection. Semin Pediatr Infect Dis. 2005;16(1):50-9.

Schleiss MR, Heineman TC. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2005;4(3):381-406.

Madden C, Wiley S, Schleiss MR, Benton C, Meinzen-Derr J, Greinwald J, Choo D. Audiometric, clinical and educational outcomes in a pediatric symptomatic congenital cytomegalovirus (CMV) population with sensorineural hearing loss. Int J Pediatr Otorhinolaryngol. 2005;69(9):1191-8.


Feedback | Notice of Privacy Practices


 
The University of Minnesota is an equal opportunity educator and employer.